Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada.


Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
04 2022
Historique:
received: 29 10 2021
revised: 12 12 2021
accepted: 22 01 2022
pubmed: 7 2 2022
medline: 9 4 2022
entrez: 6 2 2022
Statut: ppublish

Résumé

In response to the ongoing overdose crisis, some clinicians in Canada have started prescribing immediate release hydromorphone (IRH) as an alternative to the toxic unregulated drug supply. This practice is often referred to as safer supply. We aimed to identify and characterize patients receiving safer supply IRH and their prescribers in Ontario. Using provincial administrative health data, we identified individuals with opioid use disorder prescribed safer supply IRH from January 2016 to March 2020 and reported the number of initiations over time. We summarized demographic, health, and medication use characteristics among patients who received safer supply IRH, and examined select clinical outcomes including retention and death. Finally, we characterized prescribers of safer supply IRH and compared frequent and infrequent prescribers. We identified 534 initiations of safer supply IRH (447 distinct individuals) from 155 prescribers. Initiations increased over time with a peak in the third quarter of 2019 (103 initiations). Patients' median age was 42 (interquartile range [IQR] 34-50), and most were male (60.2%), urban residents, (96.2%), and in the lowest neighborhood income quintile (55.7%), with 13.9% having overdosed in the previous one year. The prevalence of HIV was 13.9%. The median duration on IRH was 272 days (IQR 30-1,244) and OAT was co-prescribed in 62.9% of courses. Death while receiving IRH or within 7 days of discontinuation was rare (≤5 courses;≤0.94 per person-year for each). Clinicians are increasingly prescribing safer supply IRH in Ontario. Patients prescribed safer supply IRH had demographic and clinical characteristics associated with high risk of death from opioid-related overdose. Short-term deaths among people receiving safer supply IRH were rare.

Sections du résumé

BACKGROUND
In response to the ongoing overdose crisis, some clinicians in Canada have started prescribing immediate release hydromorphone (IRH) as an alternative to the toxic unregulated drug supply. This practice is often referred to as safer supply. We aimed to identify and characterize patients receiving safer supply IRH and their prescribers in Ontario.
METHODS
Using provincial administrative health data, we identified individuals with opioid use disorder prescribed safer supply IRH from January 2016 to March 2020 and reported the number of initiations over time. We summarized demographic, health, and medication use characteristics among patients who received safer supply IRH, and examined select clinical outcomes including retention and death. Finally, we characterized prescribers of safer supply IRH and compared frequent and infrequent prescribers.
RESULTS
We identified 534 initiations of safer supply IRH (447 distinct individuals) from 155 prescribers. Initiations increased over time with a peak in the third quarter of 2019 (103 initiations). Patients' median age was 42 (interquartile range [IQR] 34-50), and most were male (60.2%), urban residents, (96.2%), and in the lowest neighborhood income quintile (55.7%), with 13.9% having overdosed in the previous one year. The prevalence of HIV was 13.9%. The median duration on IRH was 272 days (IQR 30-1,244) and OAT was co-prescribed in 62.9% of courses. Death while receiving IRH or within 7 days of discontinuation was rare (≤5 courses;≤0.94 per person-year for each).
CONCLUSIONS
Clinicians are increasingly prescribing safer supply IRH in Ontario. Patients prescribed safer supply IRH had demographic and clinical characteristics associated with high risk of death from opioid-related overdose. Short-term deaths among people receiving safer supply IRH were rare.

Identifiants

pubmed: 35124413
pii: S0955-3959(22)00021-4
doi: 10.1016/j.drugpo.2022.103601
pmc: PMC9949899
mid: NIHMS1875175
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
Hydromorphone Q812464R06

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103601

Subventions

Organisme : NIDA NIH HHS
ID : R25 DA037756
Pays : United States
Organisme : CIHR
ID : 153070
Pays : Canada

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tara Gomes has received grant funding from the Ontario Ministry of Health. No other authors report conflicts of interest.

Références

Lancet Infect Dis. 2020 Apr;20(4):487-497
pubmed: 31981474
J Stud Alcohol Drugs. 2020 Sep;81(5):556-560
pubmed: 33028465
CMAJ. 2020 Mar 2;192(9):E219-E220
pubmed: 32122979
J Addict Dis. 2016;35(1):22-35
pubmed: 26467975
Bull World Health Organ. 2013 Feb 1;91(2):102-23
pubmed: 23554523
Drug Alcohol Depend. 2021 Aug 1;225:108830
pubmed: 34182376
Clin Infect Dis. 2019 May 17;68(11):1862-1869
pubmed: 30239630
PLoS One. 2020 Apr 24;15(4):e0232191
pubmed: 32330184
Harm Reduct J. 2017 May 12;14(1):16
pubmed: 28494791
JAMA Psychiatry. 2016 May 1;73(5):447-55
pubmed: 27049826
PLoS One. 2011;6(6):e21748
pubmed: 21738786
COPD. 2009 Oct;6(5):388-94
pubmed: 19863368
J Addict Med. 2015 Nov-Dec;9(6):440-6
pubmed: 26484843
J Addict Med. 2022 Jul-Aug 01;16(4):433-439
pubmed: 34711742
Cochrane Database Syst Rev. 2011 Dec 07;(12):CD003410
pubmed: 22161378
Lancet. 2009 Oct 10;374(9697):1284-93
pubmed: 19819393
Br J Psychiatry. 2015 Jul;207(1):5-14
pubmed: 26135571
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Ann Intern Med. 2018 Aug 7;169(3):137-145
pubmed: 29913516
Addiction. 2011 Jan;106(1):32-51
pubmed: 21054613
Int J Drug Policy. 2020 Sep;83:102832
pubmed: 32654930
BMJ. 2020 Mar 31;368:m772
pubmed: 32234712

Auteurs

Samantha Young (S)

Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of General Internal Medicine, Department of Medicine, St. Michael's Hospital, Unity Health, Toronto, Ontario, Canada; Interdepartmental Division of Addiction Medicine, St. Paul's Hospital, Vancouver, British Columbia, Canada.

Gillian Kolla (G)

Canadian Institute for Substance Use Research, University of Victoria, Victoria, British Columbia, Canada.

Daniel McCormack (D)

ICES, Toronto, Ontario, Canada.

Tonya Campbell (T)

Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada.

Pamela Leece (P)

Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Public Health Ontario, Toronto, Ontario, Canada.

Carol Strike (C)

Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, Canada.

Anita Srivastava (A)

Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada; St. Joseph's Hospital, Unity Health, Toronto, Ontario, Canada.

Tony Antoniou (T)

ICES, Toronto, Ontario, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Family and Community Medicine, St. Michael's Hospital, Unity Health, Toronto, Ontario, Canada.

Ahmed M Bayoumi (AM)

Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of General Internal Medicine, Department of Medicine, St. Michael's Hospital, Unity Health, Toronto, Ontario, Canada; MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, Canada; Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Tara Gomes (T)

Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada; MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada. Electronic address: Tara.Gomes@unityhealth.to.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH